SCHEMBL11322639

SCHEMBL11322639

Cc1cc(=O)[nH]cc1C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 3/20 0.54
KDM4E B2RXH2 5/20 0.46
GAA P10253 1/20 0.46
HPGD P15428 1/20 0.46
HSD17B10 Q99714 1/20 0.46
KDM3B Q7LBC6 1/20 0.41
DYRK1A Q13627 1/20 0.41
CSNK2A1 P68400 3/20 0.40
PIM3 Q86V86 1/20 0.40
CLK4 Q9HAZ1 1/20 0.40
GABRP O00591 1/20 0.40
GABRD O14764 1/20 0.40
GABRA1 P14867 1/20 0.40
GABRB1 P18505 1/20 0.40
GABRG2 P18507 1/20 0.40
GABRB3 P28472 1/20 0.40
GABRA5 P31644 1/20 0.40
GABRA3 P34903 1/20 0.40
GABRA2 P47869 1/20 0.40
GABRB2 P47870 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21713969 0.83 NOTUM (0.54) NOTUMKDM4EGAAHPGDHSD17B10
SCHEMBL26240985 0.82 MAP2K2 (0.42) NOTUMKDM4EHSD17B10ALDH1A1
SCHEMBL29985287 0.80 KDM4E (0.45) NOTUMKDM4EHPGDHSD17B10KDM3B
SCHEMBL27223400 0.79 NR4A2 (0.49) KDM4EGAAHPGDHSD17B10ALDH1A1
SCHEMBL1658942 0.77 ADRA1A (0.52) KDM4EGAAHPGDHSD17B10KDM3B
SCHEMBL29857063 0.75 DYRK1A (0.50) KDM4EKDM3BDYRK1ACSNK2A1CSNK2A2
SCHEMBL29799903 0.75 KDM4E (0.41) KDM4EHSD17B10KDM3BDYRK1ACSNK2A1
SCHEMBL20606051 0.75 ALDH1A1 (0.49) KDM4EGAAHPGDHSD17B10ALDH1A1
SCHEMBL1146029 0.72 NOTUM (0.54) NOTUMKDM4EGAAHPGDHSD17B10
SCHEMBL791112 0.72

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-4258052-A APPLYING TOPICALLY YU RUEY J 1981-03-24 US claimed
US-11174250-B2 Substituted carboxamides as inhibitors of WDR5 protein-protein binding Propellon Therapeutics Inc. (CA) 2021-11-16 US disclosed
US-20190119264-A1 INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING Propellon Therapeutics Inc. (CA) 2019-04-25 US disclosed
EP-3423437-A1 INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING Propellon Therapeutics Inc. (CA) 2019-01-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11174250-B2 Substituted carboxamides as inhibitors of WDR5 protein-protein binding WDR5, WDR82, WDR1 NOTUM 1891/4885KDM4E 231/4885GAA 2790/4885
US-20190119264-A1 INHIBITORS OF WDR5 PROTEIN-PROTEIN BINDING WDR5, WDR82, WDR1 NOTUM 2691/4885KDM4E 967/4885GAA 2300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.